Endometrial Serous Adenocarcinoma Clinical Trial
Official title:
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Verified date | August 2017 |
Source | Gynecologic Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells.
Status | Completed |
Enrollment | 27 |
Est. completion date | July 16, 2016 |
Est. primary completion date | July 16, 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients with stage IIIA, or stage IIIC with positive cytologic washings/ascites, adnexal spread, or serosal involvement, or stage IV (by virtue of intraperitoneal disease spread) histologically confirmed endometrial cancer (endometrioid, serous, clear cell, squamous/adenosquamous, undifferentiated, or mixed histologies) - Patients must be optimally cytoreduced with less than or equal to 2 cm residual disease - Absolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to Common Toxicity Criteria (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0 [v3.0]) grade 1 - Platelets greater than or equal to 100,000/mm^3 (CTCAE v3.0 grade 0-1) - Hemoglobin greater than or equal to 10 g/dl (CTCAE v3.0 grade 1) - Creatinine less than or equal to 2 mg/% or 24 hour creatinine clearance > 50 ml/min - Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (CTCAE v3.0 grade 1) - Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1) - Neuropathy (sensory and motor) less than or equal to CTCAE v3.0 grade 1 - Patients must have normal ejection fraction - Patients must be enrolled within 8 weeks of surgery - Patients who have met the pre-entry requirements - Patients must have signed an approved informed consent and authorization permitting release of personal health information - Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2 Exclusion Criteria: - Metastatic disease involving lung or liver parenchyma, bone or inguinal or scalene lymph nodes - Patients with GOG performance grade of 3 or 4 - Patients with concomitant medical illness such as serious uncontrolled infection, uncontrolled angina, or serious peripheral neuropathy, which in the opinion of the treating physician, makes the protocol prescribed treatments hazardous to the patient - Patients with 3rd degree or complete heart block are not eligible unless a pacemaker is in place; patients who are on medications which alter cardiac conduction (digitalis, beta blockers, calcium channel blockers) or who have other cardiac conduction abnormalities may be placed on study at the discretion of the investigator - Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy - Patients who have received prior radiation or chemotherapy for the cancer being treated in this study |
Country | Name | City | State |
---|---|---|---|
United States | Cooper Hospital University Medical Center | Camden | New Jersey |
United States | University of Chicago Comprehensive Cancer Center | Chicago | Illinois |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | Hartford Hospital | Hartford | Connecticut |
United States | University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa |
United States | The Hospital of Central Connecticut | New Britain | Connecticut |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | Women and Infants Hospital | Providence | Rhode Island |
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Gynecologic Oncology Group | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of observed DLTs, defined as grade 3-4 hematologic or non-hematologic toxicity graded using CTCAE v3.0 | 18 weeks | ||
Primary | Maximum tolerated dose (MTD) of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IV cisplatin, determined according to dose-limiting toxicities (DLTs) graded using CTCAE v3.0 | 12 weeks | ||
Primary | MTD of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IP cisplatin, determined according to DLTs graded using CTCAE v3.0 | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
Completed |
NCT01935973 -
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03660826 -
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
|
Phase 2 | |
Completed |
NCT01642082 -
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01440998 -
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
|
Phase 1 | |
Completed |
NCT02728258 -
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00977574 -
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01225887 -
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01005329 -
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05256225 -
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03836157 -
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
|
Phase 2 | |
Suspended |
NCT04585958 -
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02142803 -
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT00807768 -
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
|
Phase 3 | |
Completed |
NCT02501954 -
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
|
Phase 3 | |
Completed |
NCT01307631 -
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02065687 -
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02874430 -
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
|
Phase 2 | |
Completed |
NCT01210222 -
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00942357 -
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
|
Phase 3 |